About Bristol Myers Squibb
Bristol Myers Squibb news and updates
Bristol-Myers Squibb Company receives financing of $8M in grants
Bristol Myers Squibb, a global biopharmaceutical company, has announced grants totaling nearly $8 million in support of efforts to help medically underserved patients and communities gain access to quality health care.
Jan 1, 2022 | philanthropynewsdigest.orgBiohaven Pharmaceuticals, Inc partners with Bristol-Myers Squibb Company
New Haven, Conn.-based Biohaven Pharmaceutical has struck a global licensing deal with Bristol Myers Squibb (BMS) to develop and market taldefgrobep alfa, an investigational therapy for treating neuromuscular diseases.
Jan 1, 2022 | fdanews.comBristol-Myers Squibb Company launched Eliquis on Dec 11th 19'.
For instance, Bristol-Myers Squibb Company and Pfizer Inc. introduced a cardiovascular drug called Eliquis (apixaban), which now has the highest sales and is demonstrated to be superior in terms of risk reductions compared to other drugs in the market.
Jan 1, 2019 | medgadget.comJones left Bristol-Myers Squibb Company as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases on Jan 28th 22'.
Dr. Jones joins Cullinan Oncology from Bristol Myers Squibb where he held positions of increasing responsibility in oncology clinical development, most recently as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases.
Jan 1, 2022 | streetinsider.comBessen retired from Bristol-Myers Squibb Company as Vice President, Head of US Medical on Feb 3rd 22'.
Dr. Bessen retired in 2016 from Bristol Myers Squibb (BMS) after 15 years in leadership positions, most recently as Vice President, Head of US Medical.
Jan 1, 2022 | businesswire.comAdagene Inc. partners with Bristol-Myers Squibb Company
Adagene has also partnered with Bristol Myers Squibb and the National Institutes of Health and has a pipeline of its own.
Jan 1, 2022 | fiercepharma.comBristol-Myers Squibb Company expands facilities to Portsmouth, Ohio, United States
Biopharmaceutical company Bristol Myers Squibb has signed a long-term lease for its newest core R&D facility in Alexandria Point, a 427,000-square-foot life sciences building in University Town Center.
Jan 1, 2022 | sandiegometro.comTemedica GmbH partnered with Bristol-Myers Squibb Company on Mar 15th 22'.
Temedica GmbH, a leading digital health and health insights company, today announced its cooperation with Bristol Myers Squibb to develop a digital companion for patients with psoriasis.
Jan 1, 2022 | biospace.comBristol-Myers Squibb Company files suit against AstraZeneca UK Ltd.
Bristol-Myers Squibb and E.R. Squibb & Sons have filed a patent infringement lawsuit against AstraZeneca Pharmaceuticals and AstraZeneca UK over the cancer treatment product durvalumab, which the latter is selling under the name Imfinzi.
Jan 1, 2022 | biospace.comBristol-Myers Squibb Company files suit against AstraZeneca plc
Bristol-Myers Squibb ( NYSE: BMY ) has filed a patent infringement lawsuit against AstraZeneca ( NASDAQ: AZN ) that argues that the U.K.-based pharma's cancer treatment Imfinzi (durvalumab) infringes on patents related to Opdivo (nivolumab).
Jan 1, 2022 | seekingalpha.comBristol-Myers Squibb Company hires Eliot Powell as Group Chief Commercial Officer
Insurance and reinsurance broker BMS Group has appointed Howden’s Eliot Powell as its new Group Chief Commercial Officer (CCO), based in London and reporting to Nick Cook, Chief Executive Officer (CEO) of BMS.
Jan 1, 2022 | reinsurancene.wsDkoding partnered with Bristol-Myers Squibb Company on Mar 23rd 22'.
Dkoding has also expanded its collaboration with Bristol Myers Squibb to jointly develop its TCER ® IMA401 targeting MAGEA4 and MAGEA8 and Dkoding plan to initiate the first-in-man clinical trial of IMA401 in the first half of 2022.
Jan 1, 2022 | dkoding.inVolastratx partnered with Bristol-Myers Squibb Company on Mar 21st 22'.
Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN) as a vulnerability for cancer cells, today announced a collaboration with Bristol Myers Squibb to discover, develop and commercialize new medicines.
Jan 1, 2022 | pharmafocusasia.comBristol-Myers Squibb Company is developing two new digital pathology algorithms
Roche Diagnostics International Ltd. is joining forces with Bristol Myers Squibb Co. (BMS) to develop two new digital pathology algorithms to support cancer assay use in clinical trials.
Jan 1, 2022 | bioworld.comBristol-Myers Squibb Company is developing cancer treatments that can be personalized
Using artificial intelligence algorithms developed by Roche to generate biomarker data from clinical trial samples, Bristol Myers Squibb will be able to develop new cancer treatments that can be personalized to a patient’s individual biology.
Jan 1, 2022 | fiercebiotech.comHousey Pharmaceutical Research Laboratories LLC partners with Bristol-Myers Squibb Company
Housey Pharma ( http://www.housey.com ) has entered into a license agreement of its core-enabling technologies for new-drug discovery with Bristol Myers Squibb.
Jan 1, 2021 | prweb.comBristol-Myers Squibb Company is developing bispecific anti-TIGIT AGEN1777 on May 1st 21'.
Bristol-Myers Squibb and Agenus Inc's are working on bispecific anti-TIGIT AGEN1777 under a May 2021 partnership.
Jan 1, 2022 | aawsat.comBristol-Myers Squibb Company invests into Silverbacktx in $65M
Since its inception in 2016, Silverback has raised $65 million in venture capital financing from OrbiMed, Bristol-Myers Squibb, and Alexandria Venture Investments.
Jan 1, 2020 | yahoo.comReviveMed Inc partnered with Bristol-Myers Squibb Company on Jul 1st 20'.
Revivemed Inc., of Cambridge, Mass., said it is pursuing an evaluation study with New York-based Bristol Myers Squibb Co. designed to leverage its artificial intelligence platform to better understand mechanisms of response and resistance to immunotherapies in patients with cancer.
Jan 1, 2020 | bioworld.comMatthew Hagan leaves Bristol-Myers Squibb Company as executive director, hematology portfolio marketing
Matthew Hagan joins Cellectar from Bristol Myers Squibb where he was executive director, hematology portfolio marketing.
Jan 1, 2022 | globenewswire.comThe Octant partners with Bristol-Myers Squibb Company
Octant also announced a collaboration with Bristol Myers Squibb.
Jan 1, 2022 | businesswire.comOctant partnered with Bristol-Myers Squibb Company on Mar 28th 22'.
Octant also recently announced a collaboration with Bristol Myers Squibb.
Jan 1, 2022 | pulse2.comBristol-Myers Squibb Company launched group of 52 physicians selected for Diversity in Clinical Trials Career Development Program on Oct 1st 21'.
For example, in October 2021, Bristol Myers Squibb, along with its partners, National Medical Fellowships (NMF) and the American Association for Cancer Research (AACR), announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program (BMSF DCTCDP).
Jan 1, 2022 | mysanantonio.comBristol-Myers Squibb Company invested into Octant in $80M on Apr 21st 22'.
On April 21, 2022, Octant, a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision medicines for complex diseases, announced an $80 million Series B financing round that was led by Catalio Capital Management and included participation from Bristol Myers Squibb and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and Fifty Years.
Jan 1, 2022 | wsgr.comBristol-Myers Squibb Company sells assets to Lotte Group in the amount of $160M
Lotte Corp is buying one of Bristol Myers Squibb ’s pharmaceutical manufacturing facilities for $160 million, as the Korean chaebol seeks to diversify its operations.
Jan 1, 2022 | bloomberg.comBristol-Myers Squibb Company is developing BBP-398 on May 12th 22'.
BridgeBio Pharma Inc (NASDAQ: BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE: BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology.
Jan 1, 2022 | yahoo.comStrategic North partners with Bristol-Myers Squibb Company
The BOBI Awards recognize excellence across the healthcare business intelligence spectrum, and Prescient Healthcare Group is delighted that Strategic North in partnership with Bristol Myers Squibb (BMS) received this highly commended nomination for their co-created design thinking approach to unlock shared decision making in metastatic melanoma.
Jan 1, 2022 | prescienthg.comBristol-Myers Squibb Company is developing targeted protein degradation therapies
Amphista Therapeutics has signed a strategic partnership and licence agreement with Bristol Myers Squibb (BMS) to discover and develop targeted protein degradation (TPD) therapies.
Jan 1, 2022 | pharmaceutical-technology.comBristol-Myers Squibb Company sold assets to Lotteworld in the amount of $160M on Apr 24th 22'.
Lotte recently bought a pharmaceutical factory in New York from U.S. drug firm Bristol Myers Squibb for $160 million.
Jan 1, 2022 | yna.co.krBristol-Myers Squibb Company launches ozanimod
Bristol Myers Squibb announced the commercial US launch of ozanimod (Zeposia) for the treatment of relapsing forms of multiple sclerosis.
Jan 1, 2020 | drugtopics.comBristol-Myers Squibb Company launched LAG-3 drug on Mar 1st 22'.
(Bristol Myers Squibb ) Bristol Myers Squibb made history in March by introducing the first LAG-3 drug as part of an Opdivo combo called Opdualag.
Jan 1, 2022 | fiercepharma.comBristol-Myers Squibb Company is developing AI algorithms that will assess clinical images on Mar 1st 22'.
Its digital pathology group in March announced a collaboration with Bristol Myers Squibb (NYSE: BMY) to develop AI algorithms that will assess clinical images.
Jan 1, 2022 | nasdaq.comBristol-Myers Squibb Company invested into Transitionbio in $50M on Jun 2nd 22'.
Transition Bio, Inc., a microfluidics-driven drug discovery platform company using biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates, today announced its $50 million Series A financing, led by Northpond Ventures and joined by Taiho Ventures, Bristol Myers Squibb and Magnetic Ventures.
Jan 1, 2022 | valdostadailytimes.comBristol-Myers Squibb Company will acquire TP Therapeutics, Inc. for $4.1B on Jun 10th 22'.
Bristol Myers said it would pay $76 a share in cash for San Diego-based Turning Point, more than Thursday's closing price of $34.16.
Jan 1, 2022 | marketwatch.comBristol-Myers Squibb Company has issues with violations of the federal securities laws
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb Company on behalf of former shareholders of Celgene Corporation who received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) for violations of the federal securities laws.
Jan 1, 2021 | law.comBristol-Myers Squibb Company sold assets to Cheplapharm Arzneimittel GmbH on Aug 1st 18'.
CHEPLAPHARM acquired the global rights to the products from Bristol-Myers Squibb (BMS) in August 2018.
Jan 1, 2019 | globalbankingandfinance.comBristol-Myers Squibb Co partnered with Owkin Inc on May 17th 22'.
(Alessandro Biascioli/iStock/Getty Images Plus) Bristol Myers Squibb will work with French biotech AI developer Owkin to design and optimize cardiovascular drug trials under a deal announced June 8.
Jan 1, 2022 | fiercebiotech.comBristol-Myers Squibb Co launched data on COVID-19 vaccine on Jun 24th 22'.
Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase 3 DAYBREAK open-label extension (OLE) study in relapsing multiple sclerosis.
Jan 1, 2022 | businesswire.comBristol-Myers Squibb Co launched post-hoc analyses from the Zeposia on Jun 24th 22'.
Bristol Myers Squibb (NYSE:BMY) today announced new post-hoc analyses from the Zeposia (ozanimod) Phase 3 DAYBREAK open-label extension (OLE) and Phase 3 SUNBEAM trials, showing early Zeposia use demonstrated cognitive benefits in people with relapsing multiple sclerosis (MS), with the greatest effect seen in people with high thalamic volume (TV), supporting an association between preserved brain volume (BV) and improved long-term cognitive outcomes.
Jan 1, 2022 | businesswire.comBristol-Myers Squibb Co acquired Juno Online Services for $9B on Jan 1st 18'.
Bristol Myers Squibb acquired Juno for $9 billion in 2018.
Jan 1, 2022 | fiercepharma.comBristol-Myers Squibb Co files suit against Xspray Pharma AB
Bristol-Myers Squibb has filed a patent infringement lawsuit against Xspray Pharma over its plan to produce a generic version of the blockbuster drug sprycel (dasatinib).
Jan 1, 2022 | lifesciencesipreview.comBristol-Myers Squibb Co sold assets to Skpharmteco on Jan 1st 17'.
SK Pharmteco acquired the Swords Campus facility from Bristol Myers Squibb for an undisclosed price in 2017.
Jan 1, 2022 | independent.ieBristol-Myers Squibb Co launches Disability Diversity in Clinical Trials
Bristol Myers Squibb (BMS) announced it has launched the Disability Diversity in Clinical Trials (DDiCT) initiative in collaboration with Disability Solutions, a US-based non-profit organization that supports companies globally to achieve true disability inclusion.
Jan 1, 2022 | njbmagazine.comBristol-Myers Squibb Co is developing app for patients living with psoriasis
Bristol Myers Squibb (BMS) will collaborate with Temedica, a digital health and health insights company, to develop an app for patients living with psoriasis.
Jan 1, 2022 | dermatologyinpractice.co.ukBristol-Myers Squibb Co is developing dual immunotherapy combinations
As part of its mission to deliver new medicines for patients, Bristol-Myers Squibb Co has continued to develop new dual immunotherapy combinations,” said Paul Basciano, development lead, relatlimab, Bristol Myers Squibb.
Jan 1, 2022 | bms.comBristol-Myers Squibb Co will partner with Massachusetts Biotechnology Council Inc on Oct 6th 22'.
On October 6, Bristol Myers Squibb (BMS) will team up with MassBio to host a Pharma Day ®, during which the global biopharma will showcase its R&D strategy and directly connect with potential collaborators across the life sciences innovation ecosystem.
Jan 1, 2022 | massbio.orgBristol-Myers Squibb Co partners with Disability Solutions
Bristol Myers Squibb is collaborating with non-profit organisation Disability Solutions on an initiative to increase diversity in clinical trials.
Jan 1, 2022 | europeanpharmaceuticalreview.comGentiBio, Inc. partnered with Bristol-Myers Squibb Co on Aug 10th 22'.
Now GentiBio, which is backed by the venture arm of Novartis, is partnering with Bristol Myers.
Jan 1, 2022 | biopharmadive.comBristol-Myers Squibb Co is developing Treg therapies on Aug 11th 22'.
GentiBio, Inc., an engineered regulatory T cells (Tregs) company, announced today that it has entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).
Jan 1, 2022 | pharmafocusasia.comWinselow leaves Bristol-Myers Squibb Co as senior vice president and general manager of US Hematology
Winselow joins Lilly from Bristol Myers Squibb, where he served as senior vice president and general manager of US Hematology before assuming his current responsibilities as senior vice president, intercontinental, earlier this year.
Jan 1, 2022 | techrseries.comBristol-Myers Squibb Co is developing in-vitro diagnostic
For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio.
Jan 1, 2022 | einnews.comBristol-Myers Squibb Co launches MS Work Space
With those statistics in mind, Bristol Myers Squibb, which markets multiple sclerosis drug Zeposia, has rolled out MS Work Space, a new website and podcast series to help employers support workers living with MS or caring for someone with the disease.
Jan 1, 2022 | fiercepharma.comBristol-Myers Squibb Co had issues with antitrust lawsuit on Jun 23rd 22'.
The payments sent today to 12,723 consumers nationwide are part of a $49.74 million settlement that resolves an antitrust lawsuit filed by states against Bristol.
Jan 1, 2022 | ossh.comBristol-Myers Squibb Co hires Germán Torres-Ortíz as managing director and head of Caribbean facultative business for BMS Re Latin America and Caribbean
BMS Group has appointed Germán Torres-Ortíz as managing director and head of Caribbean facultative business for BMS Re Latin America and Caribbean (LAC).
Aug 24, 2022 | insidepandc.comIngram leaves Bristol-Myers Squibb Co
Ingram joins imre from Bristol Myers Squibb where he led engagement planning for worldwide customer capabilities and was responsible for the integration of the acquired Celgene lymphoma myeloid hematology portfolio into the BMS digital marketing ecosystem.
Aug 28, 2022 | provokemedia.comA-Alpha Bio, Inc. partnered with Bristol-Myers Squibb Co on Aug 23rd 22'.
A-Alpha Bio, Inc. is excited to announce its collaboration with Bristol Myers Squibb (BMS) to discover molecular glue targets for protein degradation.
Aug 22, 2022 | aalphabio.comPathAI, Inc. partnered with Bristol-Myers Squibb Co on Aug 26th 22'.
PathAI, a global leader in AI-powered pathology, today announced a multi-year expanded collaboration agreement with Bristol Myers Squibb.
Aug 25, 2022 | pharmtechfocus.comRobert Plenge leaves Bristol-Myers Squibb Co as head of Translational Medicine
“We look forward to collaborating with PathAI to expand the potential application of AI in the drug development process to include translational research, clinical trials, and diagnostic advancements,” said Robert Plenge, MD, PhD, senior vice president of Bristol Myers Squibb, head of Immunology, Cardiovascular, and Fibrosis Thematic Research Center, and head of Translational Medicine.
Aug 26, 2022 | insideprecisionmedicine.comBristol-Myers Squibb Co sells assets to Lottebiologics in the amount of $160M
Lotte has agreed to buy Bristol Myers Squibb's pharmaceutical plant in East Syracuse for $160 million.
Sep 1, 2022 | syracuse.comBristol-Myers Squibb Co invested into Bighatbio in $75M on Jul 20th 22'.
BigHat Biosciences, a biotech startup developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round, led by Section 32, with participation from Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, and GRIDS Capital, among others.
Jul 19, 2022 | biopharmatrend.comBristol-Myers Squibb Co launched Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo on Jul 29th 22'.
Bristol Myers Squibb (NYSE: BMY) today announced that Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with localized renal cell carcinoma (RCC) who have undergone full or partial removal of the kidney and who are at moderate or high risk of relapse, did not meet the primary endpoint of disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR).
Jul 28, 2022 | bms.comBristol-Myers Squibb Co decreases headcount by 360
California pharmaceutical companies AbbVie and Bristol Myers Squibb reportedly plan to cut 360 employees—becoming the latest U.S. companies to reassess their headcounts as employers fear the economy could slide into recession.
Sep 17, 2022 | forbes.comBristol-Myers Squibb Co decreased headcount by 261 on Sep 19th 22'.
Yesterday Bristol Myers Squibb announced it was laying off 261 people in two different sites in San Diego, while AbbVie announced it would cut 99 jobs in Irvine, California.
Sep 20, 2022 | biospace.comOtsuka Pharmaceutical Co partnered with Bristol-Myers Squibb Co on Jan 1st 99'.
Otsuka initially developed the drug, and partnered with Bristol-Myers Squibb (BMS) in 1999 to complete development, obtain approvals, and market aripiprazole.
Sep 21, 2022 | mental-health-matters.orgBristol-Myers Squibb Co received award Best trained workforce awards on Jan 1st 22'.
The awards consisted of 10 categories, with Bristol Myers Squibb winning the Menopause friendly employer of the year and Best trained workforce awards.
Sep 26, 2022 | employeebenefits.co.ukBristol-Myers Squibb Co launches Digital Trial Software-as-a-Service solution
Bristol Myers Squibb (BMS) and ConcertAI have launched the latter’s new Digital Trial Software-as-a-Service solution for oncology, haematology, and urology.
Sep 30, 2022 | clinicaltrialsarena.comAutolus, Inc partnered with Bristol-Myers Squibb Co on Oct 4th 22'.
LONDON, October 4, 2022 - Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol Myers Squibb (NYSE: BMY).
Apr 9, 2022 | synconaltd.comBristol-Myers Squibb Co partners with Synthexlabs
(iStock / Getty Images Plus) Bristol Myers Squibb is partnering up with San Francisco biotech SyntheX to ride into the lawless land of molecular glue degrader discovery—giving the biotech the potential to pocket up to $550 million in biobucks.
Oct 4, 2022 | fiercebiotech.comMary retires from Bristol-Myers Squibb Co as Executive Secretary
Mary worked as an Executive Secretary and retired from Bristol Myers Squibb.
Sep 30, 2022 | hardincoindependent.comBristol-Myers Squibb Co partners with Carbon Footprint Ltd
BMS Group will work with Carbon Footprint Limited, a founding member of the Quality Assurance Standard for carbon offsetting, who will offset BMS’ GHG emissions through several projects aimed to tackle climate change as well as having considerable social impact.
Oct 9, 2022 | bermudareinsurancemagazine.comBristol-Myers Squibb Co partners with Tsinghua University
In order to expand its already obscene profit streams, New York-based pharmaceutical giant Bristol-Myers Squibb is partnering with Tsinghua University in communist China to develop new drugs for novel cancers and autoimmune diseases.
Oct 16, 2022 | ln24sa.comBristol-Myers Squibb Co partners with 2seventy Bio
Bristol Myers Squibb, the manufacturer of Abecma, collaborated with 2seventy Bio, Inc. on the trial.
Oct 9, 2022 | acgtfoundation.orgBristol-Myers Squibb Co hires Alex Tesei as director of European energy reinsurance
BMS Group is pleased to announce a further expansion of their specialty energy practice with the senior industry hire of Alex Tesei as director of European energy reinsurance.
Oct 19, 2022 | haggiepartners.comBristol-Myers Squibb Co is developing PRX005
Along with PRX012, it is developing PRX005, an anti-tau antibody, in conjunction with Bristol-Myers Squibb (BMS), specifically targeting an area within the microtubule binding region (MTBR) for the potential treatment of AD.
Oct 5, 2022 | biopharma-reporter.comBristol-Myers Squibb Co hires Alex Orloff as Director of Capital Markets Analytics
Insurance and reinsurance brokerage BMS Group has named Alex Orloff as Director of Capital Markets Analytics at BMS Capital Advisory, the firm’s investment banking unit.
Dec 16, 2019 | reinsurancene.wsBristol-Myers Squibb Co is developing Treg therapies for inflammatory bowel disease patients
GentiBio and Bristol Myers Squibb (BMS) have signed a multi-year partnership agreement for developing new engineered Treg therapies for inflammatory bowel disease (IBD) patients.
Aug 11, 2022 | pharmaceutical-technology.comBristol-Myers Squibb Co is developing engineered regulatory T cell therapies
GentiBio is collaborating with Bristol Myers Squibb to develop new engineered regulatory T cell (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases, which cause debilitating and life-threatening chronic inflammation of the gastrointestinal tract.
Aug 16, 2022 | seattlechildrens.orgBristol-Myers Squibb Co launched three new first-in-class drugs on Jan 1st 22'.
You may also be interested in... Bristol Myers Squibb has launched three new first-in-class drugs this year – Opdualag, Camzyos and Sotyktu – and investors are closely watching the early momentum.
Nov 16, 2022 | informa.comBristol-Myers Squibb Co is developing app for psoriasis patients on Mar 1st 22'.
Temedica announced a partnership in March with Bristol Myers Squibb to develop an app for psoriasis patients.
Nov 25, 2022 | modernhealthcare.comBristol-Myers Squibb Co is developing Treg therapies on Aug 1st 22'.
In August 2022, GentiBio, Inc. announced that it had entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).
Nov 25, 2022 | digitaljournal.comLyvgen partners with Bristol-Myers Squibb Co
Lyvgen Biopharma has partnered with Bristol Myers Squibb ( BMS ) to carry out a Phase II clinical trial of the former’s antibody, LVGN7409, plus docetaxel or nivolumab in advanced/metastatic non-small cell lung cancer (NSCLC) patients.
Nov 28, 2022 | clinicaltrialsarena.comEnvisagenics Inc. partnered with Bristol-Myers Squibb Co on Nov 29th 22'.
Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY ).
Nov 29, 2022 | prnewswire.comBristol-Myers Squibb Co launched Survivorship Today campaign on Jan 1st 19'.
When Bristol Myers Squibb launched its Survivorship Today campaign in 2019, it sought to focus on cancer survivors, a patient population that has often been overlooked.
Dec 5, 2022 | mmm-online.comBristol-Myers Squibb Co recognized as Top Socially Responsible Dividend Stock
Bristol Myers Squibb Co. (Symbol: BMY) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.9% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria.
Dec 12, 2022 | nasdaq.comBristol-Myers Squibb Co sells assets to NextSource Pharmaceuticals, LLC
NextSource Pharma, a small pharmaceutical company based in Florida, acquired the drug lomustine from Bristol-Myers Squibb, changed its brand name to Gleostine, and changed the price – by about 1,400 percent.
Jan 5, 2018 | curetoday.comBristol-Myers Squibb Co launched BMS-986354 on Dec 21st 22'.
On the other hand, Bristol unveiled BMS-986354, a Car asset based on the now discontinued orva-cel that looked highly competitive.
Dec 21, 2022 | evaluate.comBristol-Myers Squibb Co partners with The Leukemia & Lymphoma Society
Bristol Myers Squibb has a long-standing partnership with the Leukemia and Lymphoma Society (LLS) and has been the top biopharma fundraising team for Light The Night® for more than a decade.
Dec 21, 2022 | csrwire.com